Insulet Chief Technology Officer Mark Field leaves

Amit Guliani, group vice president of software engineering, will become acting chief technology officer.

By Elise Reuter • March 18, 2025

Dexcom receives warning letter based on FDA inspections of 2 plants

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek clearance for new products.

By Nick Paul Taylor • March 10, 2025

Illumina to lay off 96 San Diego employees

The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson said.

By Susan Kelly • Feb. 28, 2025

Tandem’s insulin pump tech wins FDA nod for Type 2 diabetes

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

By Elise Reuter • Feb. 27, 2025

Illumina placed on China’s unreliable entity list

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s genome sequencing market.

By Susan Kelly • Feb. 5, 2025

Beta Bionics raises $204M in IPO

The diabetes tech firm began trading this week and was valued at $966.2 million as of Thursday.

By Elise Reuter • Jan. 31, 2025

Neko Health raises $260M to expand body scan service, fund R&D

The company uses various medical devices to noninvasively check moles, the heart and more.

By Nick Paul Taylor • Jan. 28, 2025

Beta Bionics targets $114M IPO raise to fund insulin pump development

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 million in the fourth quarter.

By Nick Paul Taylor • Jan. 27, 2025

Abbott expects to launch first PFA device outside of the US this year

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

By Elise Reuter • Jan. 22, 2025

JPM25 recap: Robotics, PFA and OTC glucose sensors in the spotlight

CEOs from Medtronic, Intuitive Surgical, Boston Scientific and Dexcom were on hand this week in San Francisco to discuss the year ahead at the J.P. Morgan Healthcare Conference.

By Susan Kelly • Jan. 17, 2025

Dexcom CEO talks Stelo sensor launch, OTC strategy

Kevin Sayer said at the J.P. Morgan Healthcare Conference that Dexcom also expects to release a 15-day glucose sensor in the second half of the year.

By Elise Reuter • Jan. 15, 2025

Beta Bionics, maker of ‘bionic pancreas,’ files for IPO

Beta Bionics did not disclose the number of shares it will offer or a price range.

By Elise Reuter • Jan. 8, 2025

Abbott, Dexcom settle glucose monitor patent lawsuits

The rival companies agreed not to sue each other for the next 10 years.

By Elise Reuter • Jan. 2, 2025

Robots, AI and PFA: The top medtech Q&As of 2024

From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.

By Ricky Zipp • Dec. 20, 2024

Dexcom adds generative AI to over-the-counter CGMs

Dexcom this week began rolling out the feature, which analyzes data to provide personalized tips and recommendations.

By Elise Reuter • Dec. 18, 2024

Embecta to cut 125 jobs after ending insulin patch pump

Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay down debt.

By Elise Reuter • Dec. 6, 2024

Insulet awarded $452M in EOFlow patent fight

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

By Elise Reuter • Dec. 5, 2024

Biden administration proposes Medicare, Medicaid coverage of pricey weight loss drugs

About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration allows the rule to go into effect — at the cost of $40 billion to federal and state governments.

By Rebecca Pifer • Nov. 27, 2024

Embecta discontinues insulin patch pump development

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.”

By Elise Reuter • Nov. 26, 2024

Medtronic nets FDA nod for smart insulin pen app

The clearance paves the way for the launch of Medtronic’s Smart MDI system, which combines its InPen and Simplera continuous glucose monitor for people who take multiple daily insulin injections.

By Susan Kelly • Nov. 22, 2024

Dexcom invests $75M in Ōura, agrees to integrate smart rings and CGMs

The partnership will support data flows that enable people who use both companies’ devices to track how glucose levels affect other health metrics.

By Nick Paul Taylor • Nov. 20, 2024

Abbott opens plant in Ireland to boost Libre 3 sensor production

More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.

By Nick Paul Taylor • Nov. 19, 2024

Dean Kamen, insulin pump pioneer, wants to shake up diabetes tech

Kamen and Sequel Med Tech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology in the Twiist device.

By Elise Reuter • Updated Nov. 25, 2024

Tandem, Insulet tout Type 2 expectations as tech attracts new users

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while Tandem plans to file a Type 2 submission by year’s end.

By Ricky Zipp • Nov. 8, 2024

Dexcom chief commercial officer to retire

Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce restructuring.

By Elise Reuter • Oct. 25, 2024